Asenapine Maleate
Brand Names: Saphris
Methodology & AI Transparency ⓘ
Asenapine Maleate Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed atypical antipsychotic (51991-359, 51991-928, manufactured/labeled by Breckenridge Pharmaceutical, Inc.), Asenapine Maleate provides sublingual-route dosing across 5 mg/1 Tablet and 2.5 mg/1 Tablet under licensed medical supervision.
- 2 Real-world patient consensus: Tracked across 11 patient dosage logs with a 74% satisfaction benchmark (RxCUI RXN-51991359-1848).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $57.01 wholesale mail-order against $139.67 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Asenapine Maleate include application-site erythema (6.8%), mild local dryness (7%), transient stinging (5.7%).
Ask our AI Specialists anything about Asenapine Maleate
Asenapine Maleate Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed atypical antipsychotic (51991-359, 51991-928, manufactured/labeled by Breckenridge Pharmaceutical, Inc.), Asenapine Maleate provides sublingual-route dosing across 5 mg/1 Tablet and 2.5 mg/1 Tablet under licensed medical supervision.
Acting as a sublingual-route atypical antipsychotic moiety, Asenapine Maleate (NDC 51991-359, 51991-928, manufactured/labeled by Breckenridge Pharmaceutical, Inc.) regulates downstream signaling pathways proportional to 5 mg/1 Tablet and 2.5 mg/1 Tablet titration and patient renal/hepatic reserve.
Systemic exposure to Asenapine Maleate reflects < 5% transdermal or mucosal systemic uptake from Asenapine Maleate absorption kinetics and local esterase/enzymatic cleavage of asenapine maleate with minimal hepatic cytochrome burden, sustaining receptor engagement across a Localized tissue retention for Asenapine Maleate with minimal systemic plasma half-life half-life window (initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (asenapine maleate) response profile).
Dosing protocols (5 mg/1 Tablet or 2.5 mg/1 Tablet or 10 mg/1 Tablet or 10mg Carton of Sublingual Tablets or 2.5mg Carton of Sublingual Tablets) balance efficacy (74.00% patient satisfaction across 11 logs) against mild local dryness (7% of reports), application-site erythema (6.8% of reports), transient stinging (5.7% of reports), with strict avoidance in severe drug-induced hypersensitivity to asenapine maleate or inactive tablet/vehicle binders; prohibited co-prescriptions or physiological states specified in fda spl 2026-07-01 for asenapine maleate.
Assess baseline hepatic panels and interacting prescriptions when starting Asenapine Maleate (atypical antipsychotic).
Unstandardized herbal extracts may interact pharmacodynamically with Asenapine Maleate maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Severe drug-induced hypersensitivity to Asenapine Maleate or inactive tablet/vehicle binders
- Prohibited co-prescriptions or physiological states specified in FDA SPL 2026-07-01 for Asenapine Maleate
Logged Side-Effect Incidence (11 Reports)
Asenapine Maleate Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Asenapine Maleate)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in These findings suggest HP-3070 has a specific antihostility effect in patients with schizophrenia. The Journal of clinical psychiatry • 2022-06-06 • Phase III Randomized Trial | N = 151 | 88/100 | PMID 35687858 ↗ |
Asenapine Maleate Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $3.0881/unit (~$92.64/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $57.01 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $139.67 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $65.56 / mo | View logs ↓ |
Asenapine Maleate Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Asenapine Maleate RxNorm Concept ID | RXN-51991359-1848 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $3.0881 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $139.67 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $57.01 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 74.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Asenapine Maleate Patient Community, Cohort Filters & Dosage Logs
Deterministic Asenapine Maleate reference combining NIH RxNorm (RXN-51991359-1848), Medicaid NADAC ($3.0881/unit), and anonymous cohort outcomes (74% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Asenapine Maleate community threads and patient logs by age, biological sex, dosage, and treatment duration.